Literature DB >> 689733

Structural analysis of the cellular constituents of a fresh clinical isolate of Staphylococcus aureus, and their role in the interaction between the organisms and polymorphonuclear leukocytes in the presence of serum factors.

W W Karakawa, D A Young, J A Kane.   

Abstract

The in vitro interaction of a fresh clinical isolate of Staphylococcus aureus and polymorphonuclear leukocytes was investigated. The importance of the various cellular constituents as host immunological factors was analyzed, and the results suggested that two components, namely, an acidic polysaccharide consisting of a predominance of aminogalacturonic acid and a strain-specific mucopeptide complex, may be involved in impeding in vitro opsonization of the organism by leukocytes. Immunochemical analysis indicated that the acidic polysaccharide possessed the same immunodominant aminogalacturonic acid residues as the antiphagocytic acidic antigen of the encapsulated prototype Scott strain. Antisera derived from rabbits immunized with strain D contained two types of opsonins, those with acidic polymer specificity and those with mucopeptide complex specificity.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 689733      PMCID: PMC422023          DOI: 10.1128/iai.21.2.496-505.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Comparison of subcutaneous and intraperitoneal staphylococcal infections in normal and complement-deficient mice.

Authors:  C S Easmon; A A Glynn
Journal:  Infect Immun       Date:  1976-02       Impact factor: 3.441

2.  Structural analysis of the surface polysaccharide of Staphylococcus aureus M.

Authors:  D F Liau; J H Hash
Journal:  J Bacteriol       Date:  1977-07       Impact factor: 3.490

3.  Antibodies against staphylococcal teichoic acids and type-specific antigens in man.

Authors:  H Daugharty; R R Martin; A White
Journal:  J Immunol       Date:  1967-06       Impact factor: 5.422

4.  Immune response to surface antigens of Staphylococcus aureus and their role in resistance to staphylococcal disease.

Authors:  R D Ekstedt
Journal:  Ann N Y Acad Sci       Date:  1974-07-31       Impact factor: 5.691

5.  The relationship between group A and group C meningococcal polysaccharides and serum opsonins in man.

Authors:  R B Roberts
Journal:  J Exp Med       Date:  1970-03-01       Impact factor: 14.307

6.  Extracellular and bacterial factors influencing staphylococcal phagocytosis and killing by human polymorphonuclear leukocytes.

Authors:  P K Peterson; J Verhoef; L D Sabath; P G Quie
Journal:  Infect Immun       Date:  1976-08       Impact factor: 3.441

7.  Immunochemical analysis of a Smith-like antigen isolated from two human strains of Staphylococcus aureus.

Authors:  W W Karakawa; J A Kane
Journal:  J Immunol       Date:  1975-08       Impact factor: 5.422

8.  The individual antigenic specificity of antibodies to streptococcal carbohydrates.

Authors:  D G Braun; R M Krause
Journal:  J Exp Med       Date:  1968-11-01       Impact factor: 14.307

9.  Multiple polysaccharide antigens of group B streptococcus, type Ia: emphasis on a sialic acid type-specific polysaccharide.

Authors:  J A Kane; W W Karakawa
Journal:  J Immunol       Date:  1977-06       Impact factor: 5.422

10.  Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens.

Authors:  R C Lancefield; M McCarty; W N Everly
Journal:  J Exp Med       Date:  1975-07-01       Impact factor: 14.307

View more
  9 in total

1.  Immunological specificity of natural opsonins and their role in the cross-reactivity between Staphylococcus aureus Mardi and Escherichia coli 101.

Authors:  D A Young; P Dobson; W W Karakawa
Journal:  Infect Immun       Date:  1979-09       Impact factor: 3.441

2.  Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes.

Authors:  W W Karakawa; A Sutton; R Schneerson; A Karpas; W F Vann
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

3.  Purification and characterization of Staphylococcus aureus type 8 capsular polysaccharide.

Authors:  J M Fournier; W F Vann; W W Karakawa
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

4.  Immunochemical study of diverse surface antigens of a Staphylococcus aureus isolate from an osteomyelitis patient and their role in in vitro phagocytosis.

Authors:  W W Karakawa; D A Young
Journal:  J Clin Microbiol       Date:  1979-03       Impact factor: 5.948

5.  Phagocytic killing of encapsulated and microencapsulated Staphylococcus aureus by human polymorphonuclear leukocytes.

Authors:  S Xu; R D Arbeit; J C Lee
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

6.  Reactivity of type-specific monoclonal antibodies with Staphylococcus aureus clinical isolates and purified capsular polysaccharide.

Authors:  M J Nelles; C A Niswander; W W Karakawa; W F Vann; R D Arbeit
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

7.  Immunological specificity of heat-stable opsonins in immune and nonimmune sera and their interaction with non-encapsulated and encapsulated strains of Staphylococcus aureus.

Authors:  W W Karakawa; D A Young
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

8.  Immunoglobulin E antibodies against Staphylococcus aureus cell walls in the sera of patients with hyperimmunoglobulinemia E and recurrent staphylococcal infection.

Authors:  K Schopfer; S D Douglas; B J Wilkinson
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

9.  Serotyping and electron microscopy studies of Staphylococcus aureus clinical isolates with monoclonal antibodies to capsular polysaccharide types 5 and 8.

Authors:  H K Hochkeppel; D G Braun; W Vischer; A Imm; S Sutter; U Staeubli; R Guggenheim; E L Kaplan; A Boutonnier; J M Fournier
Journal:  J Clin Microbiol       Date:  1987-03       Impact factor: 5.948

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.